anti-CD3/anti-CD19/anti-CD33 T-cell engager (SpectraMab)

N/A

Report date: 2026/03/19 16:57:33

Base Information

Drug Nameanti-CD3/anti-CD19/anti-CD33 T-cell engager (SpectraMab)
Drug Alias Name12132
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT cell surface glycoprotein CD3 modulatorsMyeloid cell surface antigen CD33 modulators
TargetsT cell surface glycoprotein CD3Myeloid cell surface antigen CD33B-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSpectraMab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSpectraMab
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A